Aviva PLC Has $5.85 Million Stake in Teleflex Incorporated (TFX)

Share on StockTwits

Aviva PLC lessened its position in shares of Teleflex Incorporated (NYSE:TFX) by 3.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 21,990 shares of the medical technology company’s stock after selling 700 shares during the quarter. Aviva PLC’s holdings in Teleflex were worth $5,851,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Trust N.A. raised its position in Teleflex by 12.7% in the third quarter. Raymond James Trust N.A. now owns 1,877 shares of the medical technology company’s stock valued at $500,000 after purchasing an additional 211 shares during the period. DekaBank Deutsche Girozentrale raised its position in Teleflex by 7.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 3,235 shares of the medical technology company’s stock valued at $856,000 after purchasing an additional 213 shares during the period. Metropolitan Life Insurance Co. NY raised its position in Teleflex by 1.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 13,589 shares of the medical technology company’s stock valued at $3,645,000 after purchasing an additional 251 shares during the period. State Treasurer State of Michigan raised its position in Teleflex by 1.8% in the second quarter. State Treasurer State of Michigan now owns 16,730 shares of the medical technology company’s stock valued at $4,487,000 after purchasing an additional 300 shares during the period. Finally, IFM Investors Pty Ltd raised its position in Teleflex by 14.5% in the third quarter. IFM Investors Pty Ltd now owns 2,524 shares of the medical technology company’s stock valued at $672,000 after purchasing an additional 319 shares during the period. 92.42% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE TFX opened at $256.64 on Friday. The company has a market capitalization of $12.24 billion, a price-to-earnings ratio of 30.55, a PEG ratio of 2.15 and a beta of 1.14. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.51 and a current ratio of 2.26. Teleflex Incorporated has a 52-week low of $227.52 and a 52-week high of $288.78.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, November 1st. The medical technology company reported $2.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.11. The business had revenue of $609.70 million during the quarter, compared to the consensus estimate of $609.05 million. Teleflex had a net margin of 2.81% and a return on equity of 18.04%. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.12 earnings per share. Analysts predict that Teleflex Incorporated will post 9.91 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Thursday, November 15th will be paid a $0.34 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.53%. Teleflex’s dividend payout ratio (DPR) is 16.19%.

A number of brokerages have issued reports on TFX. TheStreet raised Teleflex from a “c+” rating to a “b-” rating in a research report on Wednesday, November 28th. UBS Group began coverage on Teleflex in a research report on Tuesday, November 27th. They issued a “buy” rating and a $310.00 target price on the stock. Piper Jaffray Companies boosted their target price on Teleflex to $310.00 and gave the company an “overweight” rating in a research report on Friday, November 2nd. Needham & Company LLC reissued a “buy” rating and issued a $315.00 target price on shares of Teleflex in a research report on Friday, November 2nd. Finally, Barclays began coverage on Teleflex in a research report on Monday, October 15th. They issued an “equal weight” rating and a $266.00 target price on the stock. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Teleflex presently has a consensus rating of “Buy” and an average target price of $291.67.

In other Teleflex news, Director Benson Smith sold 9,331 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $266.73, for a total value of $2,488,857.63. Following the completion of the transaction, the director now owns 77,887 shares in the company, valued at $20,774,799.51. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Thomas E. Powell sold 5,200 shares of the business’s stock in a transaction on Friday, November 23rd. The stock was sold at an average price of $254.10, for a total transaction of $1,321,320.00. Following the transaction, the insider now owns 15,351 shares of the company’s stock, valued at approximately $3,900,689.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,329 shares of company stock valued at $21,275,053. Insiders own 2.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/2018/12/08/aviva-plc-has-5-85-million-stake-in-teleflex-incorporated-tfx/3063784.html.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Article: What is a Futures Contract?

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.